Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
IntelGenx Technologies Corp. (OTC:IGXT) reported on Thursday a 32% decrease in total revenues for the first quarter of 2023, amounting to $162,000 as compared to $237,000 in the same period last year.
The company's net comprehensive loss was $2.9 million, slightly lower than the $3.0 million loss in the first quarter of 2022.
Adjusted EBITDA loss increased to $2.4 million from $2.1 million in the previous year's first quarter.
IntelGenx is a leading drug delivery company focused on the development and manufacturing of pharmaceutical films.
"IntelGenx had an eventful quarter with FDA approval of RIZAFILM® for acute migraine and partnerships for global expansion," said Andre Godin, IntelGenx's president and CFO. "We aim to provide convenient treatments for migraine and Parkinson's disease."
The company additionally secured an exclusive supply agreement and extended warrants.
Read Next: GH Research: Q1 2023 Financials And Businesses For European 5-MeO-DMT Depression Treatment Developer
Photo: Peggy und Marco Lachmann-Anke via Pixabay.
Posted In: IGXT